Cargando…

Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection

Helicobacter pylori (HP) is a Gram-negative bacterium which finds its suitable habitat in the stomach. The infection affects about half of the global population with high variability in prevalence among regions and for age. HP is the main causative agent of chronic active gastritis, peptic and duode...

Descripción completa

Detalles Bibliográficos
Autores principales: Dargenio, Costantino, Dargenio, Vanessa Nadia, Bizzoco, Francesca, Indrio, Flavia, Francavilla, Ruggiero, Cristofori, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306855/
https://www.ncbi.nlm.nih.gov/pubmed/34357014
http://dx.doi.org/10.3390/medicina57070733
_version_ 1783727911003488256
author Dargenio, Costantino
Dargenio, Vanessa Nadia
Bizzoco, Francesca
Indrio, Flavia
Francavilla, Ruggiero
Cristofori, Fernanda
author_facet Dargenio, Costantino
Dargenio, Vanessa Nadia
Bizzoco, Francesca
Indrio, Flavia
Francavilla, Ruggiero
Cristofori, Fernanda
author_sort Dargenio, Costantino
collection PubMed
description Helicobacter pylori (HP) is a Gram-negative bacterium which finds its suitable habitat in the stomach. The infection affects about half of the global population with high variability in prevalence among regions and for age. HP is the main causative agent of chronic active gastritis, peptic and duodenal ulcers, and may be the primary cause of gastric cancer or MALT lymphoma. Due to the high rate of failure of eradication therapy in various countries and the increase in antibiotic resistance reported in the literature, there is an ever wider need to seek alternative therapeutic treatments. Probiotics seem to be a promising solution. In particular, the Limosilactobacillus reuteri (L. reuteri) species is a Gram-positive bacterium and is commonly found in the microbiota of mammals. L. reuteri is able to survive the gastric acid environment and bile and to colonize the gastric mucosa. This species is able to inhibit the growth of several pathogenic bacteria through different mechanisms, keeping the homeostasis of the microbiota. In particular, it is able to secrete reuterin and reutericycline, substances that exhibit antimicrobial properties, among other molecules. Through the secretion of these and the formation of the biofilm, it has been found to strongly inhibit the growth of HP and, at higher concentrations, to kill it. Moreover, it reduces the expression of HP virulence factors. In clinical trials, L. reuteri has been shown to decrease HP load when used as a single treatment, but has not achieved statistical significance in curing infected patients. As an adjuvant of standard regimens with antibiotics and pump inhibitors, L. reuteri can be used not only to improve cure rates, but especially to decrease gastrointestinal symptoms, which are a common cause of lack of compliance and interruption of therapy, leading to new antibiotic resistance.
format Online
Article
Text
id pubmed-8306855
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83068552021-07-25 Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection Dargenio, Costantino Dargenio, Vanessa Nadia Bizzoco, Francesca Indrio, Flavia Francavilla, Ruggiero Cristofori, Fernanda Medicina (Kaunas) Review Helicobacter pylori (HP) is a Gram-negative bacterium which finds its suitable habitat in the stomach. The infection affects about half of the global population with high variability in prevalence among regions and for age. HP is the main causative agent of chronic active gastritis, peptic and duodenal ulcers, and may be the primary cause of gastric cancer or MALT lymphoma. Due to the high rate of failure of eradication therapy in various countries and the increase in antibiotic resistance reported in the literature, there is an ever wider need to seek alternative therapeutic treatments. Probiotics seem to be a promising solution. In particular, the Limosilactobacillus reuteri (L. reuteri) species is a Gram-positive bacterium and is commonly found in the microbiota of mammals. L. reuteri is able to survive the gastric acid environment and bile and to colonize the gastric mucosa. This species is able to inhibit the growth of several pathogenic bacteria through different mechanisms, keeping the homeostasis of the microbiota. In particular, it is able to secrete reuterin and reutericycline, substances that exhibit antimicrobial properties, among other molecules. Through the secretion of these and the formation of the biofilm, it has been found to strongly inhibit the growth of HP and, at higher concentrations, to kill it. Moreover, it reduces the expression of HP virulence factors. In clinical trials, L. reuteri has been shown to decrease HP load when used as a single treatment, but has not achieved statistical significance in curing infected patients. As an adjuvant of standard regimens with antibiotics and pump inhibitors, L. reuteri can be used not only to improve cure rates, but especially to decrease gastrointestinal symptoms, which are a common cause of lack of compliance and interruption of therapy, leading to new antibiotic resistance. MDPI 2021-07-20 /pmc/articles/PMC8306855/ /pubmed/34357014 http://dx.doi.org/10.3390/medicina57070733 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dargenio, Costantino
Dargenio, Vanessa Nadia
Bizzoco, Francesca
Indrio, Flavia
Francavilla, Ruggiero
Cristofori, Fernanda
Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title_full Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title_fullStr Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title_full_unstemmed Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title_short Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
title_sort limosilactobacillus reuteri strains as adjuvants in the management of helicobacter pylori infection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306855/
https://www.ncbi.nlm.nih.gov/pubmed/34357014
http://dx.doi.org/10.3390/medicina57070733
work_keys_str_mv AT dargeniocostantino limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection
AT dargeniovanessanadia limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection
AT bizzocofrancesca limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection
AT indrioflavia limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection
AT francavillaruggiero limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection
AT cristoforifernanda limosilactobacillusreuteristrainsasadjuvantsinthemanagementofhelicobacterpyloriinfection